<DOC>
	<DOC>NCT01675596</DOC>
	<brief_summary>The objective of the study is to observe the safety, efficacy and cost effectiveness of the Edwards SAPIEN XT valve for the treatment of severe calcific degenerative aortic stenosis.</brief_summary>
	<brief_title>The SOLACE-AU Clinical Trial</brief_title>
	<detailed_description>This is a multi-centre, prospective, consecutively enrolled, non-randomized clinical trial. The comparatator group will consist of subjects undergoing surgical aortic valve replacement in Cohort A of the PARTNER II Trial.</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Age &gt; 70 years STS Score &gt; 4 Heart team agrees on eligibility including assessment that TAVR or AVR is appropriate Age &lt;70 years Evidence of an acute myocardial infarction â‰¤ 30 days Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified Stroke or transient ischemic attack (TIA) within 6 months of the procedure</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Transcatheter Heart Valve</keyword>
</DOC>